Use of rituximab in patients with systemic lupus erythematosus: An update

Autoimmunity Reviews

Volumn 8, Issue 4, 2009, Pages 343-348

  García Carrasco, Mario ^a,b   Jiménez Hernández, Mario ^c,d   Escárcega, Ricardo O ^e   Mendoza Pinto, Claudia ^a   Galarza Maldonado, Claudio ^f   Sandoval Cruz, Manuel ^a   Zamudio Huerta, Leticia ^a   López Colombo, Aurelio ^a   Cervera, Ricard ^c  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^c HOSPITAL CLÍNIC   (Spain)

^d ISSSTEP   (Mexico)

^e TEMPLE UNIVERSITY HOSPITAL   (United States)

^f Hospital Monte Sinai   (Ecuador)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RITUXIMAB;

ABDOMINAL PAIN; ADULT RESPIRATORY DISTRESS SYNDROME; AGITATION; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANOREXIA; ANXIETY; AUTOIMMUNE DISEASE; BRONCHIOLITIS OBLITERANS; BRONCHOSPASM; CARDIOGENIC SHOCK; CELL INTERACTION; CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD DISEASE; CHILL; CLINICAL FEATURE; CONSTIPATION; COUGHING; CYTOPENIA; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEVER; GONADAL DISEASE; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMOLYTIC ANEMIA; HUMAN; HUMORAL IMMUNITY; HYPERGLYCEMIA; HYPERTENSION; HYPOXIA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LOW DRUG DOSE; LUNG INFILTRATE; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMORY CELL; NAUSEA; NEUTROPENIA; NIGHT SWEAT; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PATHOGENESIS; PLASMAPHERESIS; POLYCLONAL ACTIVATION; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; RASH; REVIEW; RHINITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SLEEP DISORDER; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOEMBOLISM; TINNITUS; UNSPECIFIED SIDE EFFECT; URTICARIA; VASCULITIS; VOMITING; WEIGHT REDUCTION;

ADULT; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT OUTCOME;

EID: 60949101357     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2008.11.006     Document Type: Review

References (40)

1. Cervera R. Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the "Euro-Lupus Project". Autoimmun Rev 5 (2006) 180-186
2. Diamanti A.P., Rosado M.M., Carsetti R., and Valesini G. B cells in SLE: different biological drugs for different pathogenic mechanisms. Autoimmun Rev 7 (2007) 143-148
3. Perosa F., Favoino E., Caragnano M.A., Prete M., and Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 4 (2005) 526-531
4. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., and Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46 (2002) 2673-2677
5. Thatayatikom A., and White A.J. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 5 (2006) 18-24
6. Sutter J.A., Kwan-Morley J., Dunham J., Du Y.Z., Kamoun M., Albert D., et al. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol 126 (2008) 282-290
7. Bernasconi N., Traggiai E., and Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298 (2002) 2199-2202
8. Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., and Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173 (2006) 180-187
9. Leandro M.J., Cambridge G., Edwards J.C., Ehrenstein M.R., and Isenberg D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 44 (2005) 1542-1545
10. Galarza C., Valencia D., Tobón G.J., Zurita L., Mantilla R.D., Pineda-Tamayo R., et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?. Clin Rev Allergy Immunol 34 (2008) 124-128
11. Marks S.D., and Tullus K. Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date. Paedriatr Drugs 9 (2007) 371-378
12. Marks S.D., Patey S., Brogan P.A., Hasson N., Pilkington C., Woo P., et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52 (2005) 3168-3174
13. El-Hallak M., Binstadt B.A., Leichtner A.M., Bennett C.M., Neufeld E.J., Fuhlbrigge R.C., et al. Clinical effects and safety of RTX for treatment of refractory pediatric autoimmune diseases. J Pediatr 150 (2007) 376-382
14. Nwobi O., Abitbol C.L., Chandar J., Seeherunvong W., and Zilleruelo G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol 23 (2008) 413-419
15. Willems M., Haddad E., Niaudet P., Koné-Paut I., Bensman A., Cochat P., et al., French Pediatric-Onset SLE Study Group. Rituximab therapy for childhood-onset systemic Lupus erythematosus. J Pediatr 148 (2006) 623-627
16. Perrotta S., Locatelli F., La Manna A., Cennamo L., De Stefano P., and Nobili B. Anti-CD20 monoclonal antibody (RTX) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 116 (2002) 465-467
17. Zecca M., Nobili B., Ramenghi U., Perrotta S., Amendola G., Rosito P., et al. RTX for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101 (2003) 3857-3861
18. Camous L., Melander C., Vallet M., Squalli T., Knebelmann B., Noël L.H., et al. Complete remission of lupus nephritis with RTX and steroids for induction and rituximab alone for maintenance therapy. Am J Kidney Dis 52 (2008) 346-352
19. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50 (2004) 2580-2589
20. Leandro M.J., Ehrenstein M.R., and Edwards J.C. Treatment of refractory lupus nephritis with B lymphocyte depletion. Arthritis Rheum 48 (2003) S378
21. Lindholm C., Börjesson-Asp K., Zendjanchi K., Sundqvist A.C., Tarkowski A., and Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 35 (2008) 826-833
22. van Vollenhoven R., Gunnarsson I., Welin-Henriksson E., Sundelin B., Osterborg A., Jacobson S., et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 33 (2004) 423-427
23. Gunnarsson I., Sundelin B., Jónsdóttir T., Jacobson S.H., Henriksson E.W., and van Vollenhoven R.F. Histopathologic and clinical outcome of RTX treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 56 (2007) 1263-1272
24. Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., and Isenberg D.A. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 66 (2007) 1259-1262
25. Jónsdóttir T. Treatment of refractory systemic lupus erytehamtosus with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 67 (2008) 330-334
26. Smith K.G., Jones R.B., Burns S.M., and Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 54 (2006) 2970-2982
27. Saito K., Nawata M., Nakayamada S., Tokunaga M., Tsukada J., and Tanaka Y. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 12 (2003) 798-800
28. Chehab G., Sander O., Fischer-Betz R., and Schneider M. Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus. Z Rheumatol 66 (2007) 330-336
29. Tokunaga M., Saito K., Kawabata D., Imura Y., Fujii T., Nakayamada S., et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66 (2007) 470-475
30. Hundae A., Peskoe S., Grimsley E., and Patel S. Rituximab therapy for refractory thrombotic thrombocytopenic purpura and autoimmune-mediated thrombocytopenia in systemic lupus erythematosus. South Med J 101 (2008) 943-944
31. Miyamura T., Watanabe H., Takahama S., Sonomoto K., Nakamura M., Ando H., et al. Thrombotic thrombocytopenic purpura in patients with systemic lupus erythematosus. Nihon Rinsho Meneki Gakkai Kaishi. 31 (2008) 159-165
32. Gupta D., Roppelt H., Bowers B., Kunz D., Natarajan M., and Gruber B. Successful remission of thrombotic thrombocytopenic purpura with rituximab in a patient with undifferentiated connective tissue disorder. J Clin Rheumatol 14 (2008) 94-96
33. Fukushima T., Dong L., Sakai T., Sawaki T., Miki M., Tanaka M., et al. Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus. Lupus 17 (2008) 210-214
34. López Carmona D., Pérez de Pedro I., de Ramón E., and Camps García M.T. Rituximab as treatment for thrombocytopenic thrombotic purpura associated with systemic lupus erythematosus. Med Clin (Barc) 129 (2007) 797-798
35. Limal N., Cacoub P., Sène D., Guichard I., and Piette J.C. RTX for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Lupus 17 (2008) 69-71
36. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bovabdallah R., et al. CHOP chemotherapy plus rtuximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-342
37. Rosado M., Chao H., and Rose M. Severe acute thrombocytopenia following rituximab therapy. Leuk Lymphoma 48 (2007) 2239-2240
38. Molloy E.S., and Cabrese L.H. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: Are patients with systemic lupus erythematosus at particular risk?. Autoimmun Rev (2008 Aug 9) [Epub ahead of print]
39. Pescovitz M.D. Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. Am J Transplant 6 (2006) 859-866
40. Agarwal A., Vieira C.A., Book B.K., Sidner R.A., Fineberg N.S., and Pescovitz M.D. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant 4 (2004) 1357-1360